Teva Scores Earliest Generic License For Allergan's Linzess

Law360 (January 22, 2020, 6:55 PM EST) -- Allergan PLC and Ironwood Pharmaceuticals Inc. have agreed to give Teva Pharmaceuticals USA a license to sell generic versions of the irritable bowel syndrome medication Linzess in March 2029, winning the earliest launch date of the various companies sued for infringement.

Under the settlement, Teva will get to sell its 145 and 290 microgram dosages of the drug starting on March 31, 2029, almost a year before the next competitor, Novartis unit Sandoz Inc. They will be followed later in 2030 and 2031 by Mylan Pharmaceuticals Inc., Sun Pharma and Aurobindo Pharma Ltd.

"This latest [abbreviated new drug application] settlement with...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!